 Chemical Structure.png)
Physicochemical Properties
| Exact Mass | 961.422 |
| CAS # | 4037-01-8 |
| Related CAS # | 4037-01-8 4-10-Semax ACTH - msh (4-10); Adrenocorticotropic hormone 4-10 Met-glu-his-phe-arg-trp-gly Msh-acth (4-10); |
| PubChem CID | 123787 |
| Appearance | White to off-white solid powder |
| Density | 1.48g/cm3 |
| Vapour Pressure | 4.64E-09mmHg at 25°C |
| Index of Refraction | 1.547 |
| LogP | 9.435 |
| Hydrogen Bond Donor Count | 13 |
| Hydrogen Bond Acceptor Count | 14 |
| Rotatable Bond Count | 29 |
| Heavy Atom Count | 68 |
| Complexity | 1740 |
| Defined Atom Stereocenter Count | 6 |
| SMILES | CSCCC(N)C(NC(C(NC(C(NC(C(NC(C(NC(C(NCC(O)=O)=O)CC1=CNC2=CC=CC=C12)=O)CCCNC(N)=N)=O)CC3=CC=CC=C3)=O)CC4=CN=CN4)=O)CCC(O)=O)=O |
| InChi Key | HAAUASBAIUJHAN-LXOXETEGSA-N |
| InChi Code | InChI=1S/C44H59N13O10S/c1-68-17-15-29(45)38(62)53-32(13-14-36(58)59)41(65)57-35(20-27-22-48-24-52-27)43(67)55-33(18-25-8-3-2-4-9-25)42(66)54-31(12-7-16-49-44(46)47)40(64)56-34(39(63)51-23-37(60)61)19-26-21-50-30-11-6-5-10-28(26)30/h2-6,8-11,21-22,24,29,31-35,50H,7,12-20,23,45H2,1H3,(H,48,52)(H,51,63)(H,53,62)(H,54,66)(H,55,67)(H,56,64)(H,57,65)(H,58,59)(H,60,61)(H4,46,47,49)/t29-,31-,32-,33-,34-,35-/m0/s1 |
| Chemical Name | (4S)-4-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-5-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-(carboxymethylamino)-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid |
| Synonyms | Acth (4-10) Related CAS# |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| ln Vitro | Adrenocorticotropic hormone (human) (ACTH (4-10), which exclusively binds to MC4-R, is the core sequence of all melanocortins. After six weeks of continuous treatment, ACTH (4–10) in humans enters the cerebral fluid compartment through intranasal administration and causes complete body fat reduction [1]. |
| References |
[1]. Intranasal application of the melanocortin 4 receptor agonist MSH/ACTH(4-10) in humans causes lipolysis in white adipose tissue. Int J Obes (Lond). 2012 May;36(5):703-8. |
Solubility Data
| Solubility (In Vitro) | DMSO : ~25 mg/mL (~25.99 mM) |
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (2.60 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (2.60 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 2.5 mg/mL (2.60 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |